Interventional device developer Guidant reported preliminary first-quarter revenues for fiscal 2004 of $934 million.
The unaudited numbers include approximately $25 million in expenses for in-process research and development, including the company's previously announced acquisition of AFx, the Indianapolis-based vendor said.
By AuntMinnie.com staff writersApril 7, 2004
Related Reading
Guidant completes stent trial enrollment, April 1, 2004
Guidant, Johnson & Johnson ink stent deal, February 27, 2004
Boston Scientific, Guidant settle litigation, February 23, 2004
Guidant ups quarterly dividend, sets repurchasing plan, February 18, 2004
Guidant acquires AFx, February 10, 2004
Copyright © 2004 AuntMinnie.com